LXEO
Lexeo Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +2.6% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +3 | 35.14M | $163.68M | +8 | −5 |
| Q1 2026 | 64 | -1 | 34.99M | $201.02M | +4 | −5 |
| Q4 2025 | 65 | +1 | 34.14M | $338.98M | +1 | n/a |
| Q3 2025 | 16 | +1 | 14.53M | $96.47M | +1 | n/a |
| Q2 2025 | 12 | -2 | 12.40M | $49.85M | n/a | −2 |
| Q1 2025 | 11 | +1 | 6.39M | $22.16M | +2 | −1 |
| Q4 2024 | 10 | +3 | 6.97M | $45.84M | +3 | n/a |
| Q3 2024 | 6 | +1 | 6.33M | $57.26M | +1 | n/a |
| Q2 2024 | 5 | n/a | 5.51M | $88.42M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 2.72M | 0.0% | $17.92M | 0.0% | Held | 3 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 2.21M | -14.9% | $14.54M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 750.24K | +102.5% | $4.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 567.38K | +2.6% | $3.73M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 457.40K | n/a | $3.01M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 141.95K | +282.5% | $934,038 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 76.98K | +48.4% | $506,535 | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 17.79K | New | $117,084 | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 10.71K | New | $70,472 | 0.0% | New | 1 | SEC ↗ ×3 |
| 10 | T. Rowe Price ✦ | 10.43K | New | $69,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $117,084 | 0.0% |
| AQR Capital Management | $70,472 | 0.0% |
| T. Rowe Price | $69,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 137 holders, 79.80M shares, $457.81M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.35K sh · $16,562
Officer · 1.30K sh · $6,464
Officer · 4.12K sh · $20,203
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology